McPhersons (ASX:MCP) - Resigned CEO & Managing Director, Laurie McAllister
Resigned CEO & Managing Director, Laurie McAllister
Source: The CEO Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9
  • Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth
  • One of his highlights is the successful acquisition of Global Therapeutics in NSW
  • In the interim, Non-Executive Director Grant Peck will replace Laurie to aid in the transition to a more permanent holder
  • McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course
  • Company shares are down 6.8 per cent and are trading at $1.17

Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9.

Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth.

One of his highlights is the successful acquisition of Global Therapeutics in Byron Bay, NSW.

Before joining McPherson’s, Laurie worked at Coca-Cola for 23 years, where he had a stint as the Chief Commercial & Marketing Officer for Japan.

Laurie will remain available for a short period of time to assist McPherson’s executive team if required.

In the interim, Non-Executive Director Grant Peck will replace Laurie, effective December 10. This will provide continuity and aid in the transition to a more permanent holder.

Grant has been a Non-Executive Director since December 2017 and is also a member and Chairman of McPherson’s Audit, Risk Management and Compliance Committee.

McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course.

Company shares are down 6.8 per cent and are trading at $1.17 at 2:10 pm AEDT.

mcp by the numbers
More From The Market Online
Close up of CSL sign on the office building in Melbourne, Victoria, Australia.

CSL profit drop only deepens what has already been grim reporting week

CSL Ltd has backed up its chaotic Tuesday – where the board dumped Paul McKenzie –…

Paradigm Biopharmaceuticals to boost oral treatment of osteoarthritis for animals

Paradigm Biopharmaceuticals (ASX: PAR) is co-developing a novel oral combination therapy for the treatment of osteoarthritis…
MEG scan concept AI gen

Compumedics snags sixth order for Orion LifeSpan at $4.2M heading to Shandong

Compumedics has inked a fresh $4.2M order to kick off CY26 with a sixth unit of…
A woman with a sign and a sad face

Last year’s anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in